Therefore, these results support the hypothesis that the BRD7/BIRC2 regulatory axis is involved in carcinogenesis and tumor progression and that targeting BRD7 and BIRC2 is a potential strategy for diagnosing and treating NPC. Here, BIRC2 is linked to neoplasm.